207 related articles for article (PubMed ID: 35720407)
21. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells.
Sanjabi S; Mosaheb MM; Flavell RA
Immunity; 2009 Jul; 31(1):131-44. PubMed ID: 19604492
[TBL] [Abstract][Full Text] [Related]
22. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.
Hao Y; Baker D; Ten Dijke P
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195692
[TBL] [Abstract][Full Text] [Related]
23. [TGF-β signaling pathways in cancers].
Talar B; Czyż M
Postepy Hig Med Dosw (Online); 2013 Sep; 67():1008-17. PubMed ID: 24088545
[TBL] [Abstract][Full Text] [Related]
24. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
Gorelik L; Flavell RA
Nat Med; 2001 Oct; 7(10):1118-22. PubMed ID: 11590434
[TBL] [Abstract][Full Text] [Related]
25. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo.
Tinoco R; Alcalde V; Yang Y; Sauer K; Zuniga EI
Immunity; 2009 Jul; 31(1):145-57. PubMed ID: 19604493
[TBL] [Abstract][Full Text] [Related]
26. CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression.
Zloza A; Jagoda MC; Lyons GE; Graves MC; Kohlhapp FJ; O'Sullivan JA; Lacek AT; Nishimura MI; Guevara-Patiño JA
Cancer Immunol Immunother; 2011 Feb; 60(2):291-7. PubMed ID: 21193909
[TBL] [Abstract][Full Text] [Related]
27. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
28. The soluble transforming growth factor-beta receptor: advantages and applications.
Russo LM; Brown D; Lin HY
Int J Biochem Cell Biol; 2009 Mar; 41(3):472-6. PubMed ID: 18339576
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance.
Zhang L; Yi H; Xia XP; Zhao Y
Autoimmunity; 2006 Jun; 39(4):269-76. PubMed ID: 16891215
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor-beta signaling in cancer invasion and metastasis.
Leivonen SK; Kähäri VM
Int J Cancer; 2007 Nov; 121(10):2119-24. PubMed ID: 17849476
[TBL] [Abstract][Full Text] [Related]
32. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
33. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect.
Joshi A; Cao D
Front Biosci (Landmark Ed); 2010 Jan; 15(1):180-94. PubMed ID: 20036814
[TBL] [Abstract][Full Text] [Related]
34. TGF-β cytokine signaling promotes CD8+ T cell development and low-affinity CD4+ T cell homeostasis by regulation of interleukin-7 receptor α expression.
Ouyang W; Oh SA; Ma Q; Bivona MR; Zhu J; Li MO
Immunity; 2013 Aug; 39(2):335-46. PubMed ID: 23932572
[TBL] [Abstract][Full Text] [Related]
35. Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.
Petrausch U; Jensen SM; Twitty C; Poehlein CH; Haley DP; Walker EB; Fox BA
J Immunol; 2009 Sep; 183(6):3682-9. PubMed ID: 19692636
[TBL] [Abstract][Full Text] [Related]
36. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
[TBL] [Abstract][Full Text] [Related]
37. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
38. Role of TGF-β and the tumor microenvironment during mammary tumorigenesis.
Taylor MA; Lee YH; Schiemann WP
Gene Expr; 2011; 15(3):117-32. PubMed ID: 22268294
[TBL] [Abstract][Full Text] [Related]
39. Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.
Xue G; Zippelius A; Wicki A; Mandalà M; Tang F; Massi D; Hemmings BA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26071042
[TBL] [Abstract][Full Text] [Related]
40. TGF-beta: a master switch in tumor immunity.
Gigante M; Gesualdo L; Ranieri E
Curr Pharm Des; 2012; 18(27):4126-34. PubMed ID: 22630082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
